Ishares Biotechnology Etf (IBB) Technical Analysis
$154.18▲0.5%
Market is closed - opens 7 PM, 20 Oct 2025
Insights
- Ishares Biotechnology Etf is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Ishares Biotechnology Etf stock suggests that it is a good time to sell or bad time to initiate a fresh position
- Based on analysis of the Moving Averages technical indicator, Ishares Biotechnology Etf stock is in a uptrend ↗️
- Based on analysis of the Pivot Points, the current market trend for Ishares Biotechnology Etf stock suggests that it is a good time to buy
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 72.1 | Sell |
Stochastic | 84.97, 87.65 | Sell |
Ultimate Oscillator | 56.35 | Neutral |
Stochastic Relative Strength Index | 92.85, 87.07 | Neutral |
Moving Average Convergence Divergence | 3.29, 3.01 | Buy |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 151.82 | Buy |
20 | 148.09 | Buy |
50 | 142.81 | Buy |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 151.53 | Buy |
20 | 148.98 | Buy |
50 | 143.66 | Buy |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 151.77 | Neutral |
20 | 147.95 | Neutral |
50 | 143.52 | Buy |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 154.05 | Buy |
20 | 153.31 | Buy |
50 | 150.6 | Buy |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 154.13 | Sell |
20 | 154.24 | Buy |
50 | 152.78 | Buy |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 159.36 |
Resistance L2 | 157.86 |
Resistance L1 | 155.64 |
Pivot Point | 154.14 |
Support L1 | 151.92 |
Support L2 | 150.42 |
Support L3 | 148.2 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.